Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Northwestern University
Ohio State University
Dana-Farber Cancer Institute
Scripps Clinic
Northwell Health
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: October 17, 2012
Last updated: August 18, 2016
Last verified: August 2016